Fig. 2. Trends of positivity for aPL, ACL IgG and IgM, anti-β2-GPI IgG, and ANA among patients treated with VPA (A) and CBZ (B) before and at 6, 12, and 24 months after treatment initiation. ACL: anticardiolipin antibodies, ANA: antinuclear antibodies, anti-β2-GPI: anti-β2-glycoprotein I antibodies, aPL: antiphospholipid antibodies, CBZ: carbamazepine, Ig: immunoglobulin, OR: odds ratios, VPA: valproate.
